Introduction
============

Since the turn of 20th century neural transplantation has been studied as a potential therapeutic strategy for neural reconstruction and repair ([@B16]). Initial attempts with engraftment of neural tissue in lower vertebrates remained largely unsuccessful with most studies concluding that the adult brain was inhospitable for graft survival ([@B122]). However, several early studies showed promise with engraftment of developing tissue ([@B35]; [@B112]; [@B22]). Notably, one study ([@B22]) demonstrated viability of embryonic neocortical grafts dissected from 15 to 20 days old embryos transplanted in the young mammalian brain. Strikingly, the engrafted cells differentiated and migrated such that the graft showed laminar features and cell morphologies characteristic of the developing cerebral cortex. Later, transplanted neonatal and embryonic cells were shown to develop normal synaptic afferent and efferent connections with host brain and spinal neurons ([@B9]; [@B74]; [@B60]). Moreover, differentiation and integration of transplanted cells within the adult striatum and hippocampus was shown to be associated with improvements in motor coordination and spatial learning ([@B72]; [@B40], [@B39]; [@B8]). Later studies revealed details of the anatomical and functional integration of the grafted tissue into host circuits: neurons within intraspinal grafts that were effective in improving motor function were shown to extend axons along white matter tracts rostrally and caudally ([@B89]; [@B60]; [@B68]), and form synaptic relays ([@B26]; [@B73]). Together, these studies revealed wide ranging potential for neural stem cell transplantation in CNS disease therapeutics.

Factors Affecting Viability and Functionality of A Neuronal Transplant
======================================================================

In several studies the ideal age of embryonic donor tissue has been shown to depend on the developmental stage of the donor tissue, the time window including neuronal proliferation and migration being optimal ([@B6]; [@B65]). This is consistent with the finding that isolated hippocampal neurons that have recently completed DNA synthesis and are in the process of migration showed long term survival in cultures as opposed to post-mitotic cells dissociated from the ventricular zone or the cortical plate ([@B6]). Other favorable attributes of young tissue may include their relative insusceptibility to transplant procedure related trauma, as well as their particularly low 0~2~ consumption rate which may buoy their viability in new environments during the initial days after implantation ([@B102]).

A major objective of transplant studies has been to determine factors that allow the grafted cells to integrate functionally into host circuits, as such integration is thought to be important for sustainable therapeutic effects. In early studies it was noted that some types of transplanted embryonic cells displayed minimal dispersion, with functional effects often limited to graft site. For example, while cells within embryonic nigral tissue grafted into the striatum of 6-OHDA lesioned rats differentiate into dopamine neurons, the neurons do not disperse, but rather form a dopamine "island" near the site of transplantation within the striatum. Considering these observations, major factors contributing to a transplant's long term functionality would be the age of donor tissue, its ability to demonstrate widespread dispersion and integration within host, as well as the use of disease relevant cell types.

Interneuron Progenitors As A Candidate For Cell Based Therapy
=============================================================

While the early studies served as proof-of-principle for the concept of cell based therapy, mechanisms by which transplanted cells modify diseased brain circuitries have remained largely unknown. With refined knowledge of neurodevelopment ([@B80]; [@B86]; [@B38]) studies carried out over the past two decades have now begun to offer mechanistic insights and renewed evidence for the therapeutic efficacy of cell transplantation in CNS diseases. Of particular relevance has been the use of γ-amino butyric acid (GABA)-ergic inhibitory neuron precursors ([@B126]; [@B114]; [@B106]) (**Figure [1](#F1){ref-type="fig"}**). Constituting only about 20% of the adult cortical neuronal population, inhibitory neurons are potent regulators of normal brain function, sculpting the excitation-inhibition balance and entraining activity of neuron ensembles in brain circuits ([@B61]; [@B62]; [@B67]). Maturation of GABA circuits has been shown to set off and regulate critical period plasticity in brain sensory systems, offering a putative neurobiological handle with which to interrogate neurodevelopmental origins of neurological disorders ([@B55]). As such imbalances in excitation-inhibition and dysfunction of inhibitory interneurons are hypothesized to underlie several neurological disorders like schizophrenia (SCZ; [@B50]), autism spectrum disorders ([@B96]), Alzheimer's disease (AD; [@B4]), Parkinson's disease (PD; [@B99]), epilepsy ([@B82]), and neuropathic pain (NP) ([@B83]).

![**Interneuron development within the forebrain.** Schematic showing coronal sections of the rodent anterior and posterior telencephalon. Shown are the pallial and subpallial neurogeneic niches and their gene expression patterns. Following the discovery of tangentially migrating neurons in the developing cortex ([@B119], [@B120]) several cell lineage studies demonstrated that many of these neurons originated in the ventral telencephalic ganglionic eminences and the POA and ultimately matured into GABAergic interneurons. For example, ablation of the embryonic ventral telecephalon or mutation of the homeodomain transcription factor gene Dlx1/2 heavily expressed in this region results in a dramatic loss of neocortical GABAergic neuron populations ([@B3]). Ventral fate inducing sonic hedgehog(SHH) signaling has been shown to specify PV and SST expressing interneuron differentiation from ventral telencephalic progenitors in culture and *in vivo* ([@B128]; [@B115]). Several other homeobox genes such as Mash1 ([@B20]), Nkx2.1 ([@B108]), Lhx6 ([@B70]), and FGFR ([@B48]), as well as guidance cues such as the chemorepulsive semaphorin/neuropilin ([@B76]) and chemoattractive neuregulin-1/ErbB4 ([@B37]) interactions have been shown to be critical for proper direction and selection of GABAergic cell identity, subtype and migration. Genetic fate mapping of transplanted embryonic cells in cultures or *in utero* has revealed that MGE gives rise to PV- and SST-, while CGE gives rise to CR-, VIP- and Reelin-expressing interneurons, with each cell group having a distinct spatio-temporal origin ([@B88]; [@B127]; [@B15]; [@B81]; [@B97]). In addition, the POA has been shown to be the origin of at least 10 percent of GABAergic interneurons comprising of PV-, SST- and a small percentage of VIP-, NOS-, and CR-expressing interneurons ([@B41]). Abbreviations: LGE, MGE, CGE (lateral, medial, caudal ganglionic eminence); POA (preoptic area); CB (cabindin), CR (calretinin), PV (parvalbumin), SST (somatostatin), NPY (neuropeptide Y), RLN (reelin), NOS (nitrous oxide) expressing interneurons.](fncir-10-00064-g001){#F1}

Epilepsy
========

Impaired inhibition has been described as a key pathognomonic feature in animal models of ([@B103]; [@B25]) and human patients with ([@B31]; [@B79]) epilepsy. For example, studies in temporal lobe epilepsy, the most common type in adults, have revealed deficits in hippocampal pyramidal neuron distal dendritic domain-targeting interneurons, including interneuron subpopulations expressing somatostatin (SST; [@B13]; [@B25]; [@B63]), neuropeptide Y (NPY; [@B79]; [@B107]), and calbindin (CB; [@B124]). In addition, a decrease in the density of hippocampal basket and chandelier parvalbumin (PV) immunoreactive cells has been reported ([@B32]; [@B5]; [@B90]); however, perisomatic GABA innervation appears to be intact ([@B125], [@B123]). Despite compensatory sprouting of interneurons ([@B79]; [@B5]) imbalances in input-output relationship of pyramidal cells ([@B25]) result in abnormal cortical network activity ([@B90]). Introducing functional GABAergic neurons hence provides a means of replacing lost or dysfunctional inhibitory cells and tempering increased electrical activity seen in epilepsy.

Many of the early interneuron progenitor transplantation studies were carried out in animal models of epilepsy. [@B1] provided the first electrophysiological evidence of functional integration of MGE derived neuronal precursors grafted into the juvenile brain. In this study, grafted MGE cells within the hippocampus migrated up to ∼5 mm from injection site at 2 months after transplantation, acquired molecular markers of mature GABAergic interneurons \[by expressing GABA, PV, SST, calretinin (CR), and NPY\] and increased GABA mediated synaptic inhibition in regions containing transplants. In a series of follow-up studies, therapeutic efficacy of MGE progenitors was demonstrated by the reduction of severity and frequency of seizures in genetic ([@B7]; [@B49]) and acquired ([@B58]; [@B54]; [@B59]) rodent models of epilepsy and hippocampal disinhibition ([@B17]; [@B117]). Notably, while MGE cell transplantation in the hippocampus increased inhibitory post-synaptic current (IPSC) frequencies in host pyramidal ([@B7]) and granule cells ([@B54]), it did not significantly alter IPSC properties of host interneurons ([@B7]), whose inhibition is mediated by interneuron subclasses generated from the caudally located CGE cells ([@B47]; [@B126]; [@B19]). Remarkably, therapeutic efficacy was demonstrated as early as 2.5 weeks following transplantation suggesting possible roles for non-synaptic mechanisms in disease amelioration (**Figure [2](#F2){ref-type="fig"}**; [@B30]). Translational significance of these findings has been tested using transplantation of human pluripotent stem cell derived MGE cells in a pilocarpine-induced temporal lobe epilepsy mouse model ([@B27]; [@B57]). While MGE transplants have been shown to increase both synaptic and extrasynaptic inhibition onto host pyramidal neurons ([@B7]), activation of extrasynaptic GABA receptors was reported as the basis of MGE precursor transplantation induced amelioration of seizure activity in the cortex ([@B59]). Given the differential involvement of heterogeneous interneuron populations in the compensatory and epileptogenic mechanisms, including disease initiation and exacerbation ([@B23]; [@B93]), GABA interneuron transplants may prove therapeutic for some types or stages of epilepsy. Key to the success of transplants will be to identify which types or stages of epilepsy can benefit and determine the effective composition of the transplant. This will be aided by rapidly developing technologies that allow high throughput generation of developmentally and functionally distinct interneuron subclasses ([@B33]; [@B24]).

![**Toward a mechanistic understanding of transplant induced therapeutics.** Transplanted GABAergic interneurons make synaptic connections and enhance inhibitory tone within the host brain region ([@B1]; [@B7]). The importance of these new synaptic connections has been demonstrated in the mature visual cortex where interneuron progenitor implantation but not pharmacological GABA augmentation induces cortical plasticity and reopening of critical period ([@B36]; [@B55]; [@B105]; [@B29]). This has been attributed to the numerous, individually weak inhibitory connections made by the transplanted neurons which may trigger local circuit reorganization ([@B105]). However, given that the behavioral effects of GABAergic interneuron transplants are not phenocopied by local pharmacological enhancement of GABA transmission, and sparseness of transplanted neurons relative to the host population, it has been hypothesized that therapeutic effects of transplants may be mediated by mechanisms beyond that of GABA replacement ([@B42]; [@B106]). Intriguingly, transplanted neural stem cells have been demonstrated to rescue dysfunctional host dopamine neurons in MPTP-treated aged animals ([@B91]). Other proposed effects independent of synaptic connections with host neurons include secretion of neuroprotective factors ([@B18]; [@B98]; [@B69]; [@B45]). In addition transplanted neural cells have been proposed to create homeostatic environments by releasing factors that repair and counter inflammation and scarring ([@B94]; [@B66]). More recently, interrogation of host circuit physiology following engraftment of undifferentiated and non-integrating cells revealed a dose-dependent dampening of cortical excitability and depletion of host cell populations underscoring the importance of engraftment density in designing cell based therapeutic protocols ([@B121]). Considering the wide-ranging repertoire of transplant-induced effects, discovery of molecular mechanisms underlying these may uncover novel treatment targets in the future.](fncir-10-00064-g002){#F2}

Schizophrenia and Cortical Plasticity
=====================================

Reductions in SST and PV expressing neurons or functional markers thereof have been observed in the hippocampus and prefrontal cortex in postmortem brains of patients with SCZ ([@B52], [@B51]; [@B84]; [@B64]). Indeed, disturbances in synchronous cortical oscillations, generated by fast spiking PV neurons ([@B104]) and that are correlated with cognitive functions, are a physiological feature of SCZ ([@B87]). Moreover, increased hippocampal blood volume, a proxy for metabolic activity, a reliable feature of SCZ and correlate of psychosis, can be produced by functional deficits in GABAergic interneurons ([@B100]; [@B42]).

Exploring the role of cortical interneurons in schizophreniform cognitive deficits in mice, [@B109] demonstrated that transplantation of MGE cells in the cortex can prevent phencyclidine induced behavioral deficits, possibly via modulation of local cortical circuitry ([@B105]; [@B56]). Moreover, in a genetic mouse model displaying a relatively selective deficit in hippocampal PV interneurons ([@B44]), transplantation of MGE cells into the hippocampus reversed increased hippocampal activity (as measured with functional magnetic resonance imaging), increased midbrain dopamine neuron activity, increased response to psychostimulants and impaired hippocampus dependent cognition ([@B42]). Given the central role of GABA in controlling the timing of critical period plasticity ([@B55]) MGE cells were transplanted in the visual cortex to test whether transplantation of inhibitory cells could induce a plasticity response ([@B110]). Remarkably, MGE cell transplantation either before ([@B105]) or after ([@B29]) the endogenous critical period induced ocular dominance plasticity and reactivated a new critical period that reversed visual impairments in amblyopic mice. Importantly both PV and SST neuronal populations were shown to be sufficient to drive ocular dominance plasticity but grafts depleted of both PV and SST populations were not ([@B110]). Intriguingly, maturing GABA neurons formed numerous but individually weak synaptic connections with host neurons suggesting a potential reorganization of local cortical circuitry. Sufficiency of both PV and SST interneuron populations to induce plasticity in the visual cortex raises an interesting question as to whether the same also holds true for other brain regions and the spinal cord, as it may have implications for developing refined cell based therapies.

Alzheimer's Disease
===================

GABAergic control of synaptic plasticity is a key aspect of hippocampus dependent learning as it relates to encoding and retrieval of memories ([@B95]). AD patients have been shown to have decreased GABA and SST immunoreactivity in the cerebral cortex ([@B28]; [@B46]), and in late-onset familial and sporadic AD, the risk gene apolipoprotein (apo) E4 polymorphism exacerbates SST dysfunction ([@B46]). In addition, misfolded proteins such as amyloid-β that are seen in early-onset autosomal dominant AD cause inhibitory interneuron impairments resulting in excitation-inhibition imbalances and network hyperexcitability that is in turn associated with learning and memory deficits ([@B92]; [@B4]; [@B116]). In particular, PV cell dysfunction has been causally linked to disturbances in cortical network oscillations and cognitive impairments in mice expressing human amyloid precursor protein ([@B116]). Indeed, AD patients are known to have increased incidence of epileptic events ([@B2]).

In septo-hippocampal lesioned mice, intrahippocampal transplantation of subventricular zone-expanded neural stem cells ([@B53]) or human embryonic stem cell induced MGE cells ([@B71]) were shown to reverse learning and memory deficits. Importantly, control experiments involving transplants of spinal progenitors failed to correct these deficits, highlighting the requirement of specific neuronal progenitors in a given target region to achieve functional replacement ([@B71]). These findings were later extended in two genetic mouse models of AD: apoE4 knock-in mice with or without amyloid-β protein accumulation. Importantly, MGE derived cells showed functional integration in the presence of amyloid aggregation and restored cognitive function thus demonstrating interneuron progenitors' ability to integrate and modify diseased circuits in toxic environments ([@B113]). Given the strong evidence of impaired synaptic inhibition ([@B14]) and network oscillatory activity ([@B2]) in AD, GABA cell replacement strategies especially those employing fast spiking PV neurons could be a promising therapeutic avenue.

Parkinson's Disease
===================

Grafts of dopaminergic cell suspensions into 6-hydroxydopamine (6-OHDA) lesioned striatum are known to restore motor deficits ([@B40]). However, a critical limitation of dopaminergic cell grafts is the inability of transplanted cells to disperse in host tissue, limiting the functional recovery to graft site. Intriguingly, local striatal GABAergic interneuron population activity has been shown to sculpt basal ganglia output ([@B111]) and abnormalities in inhibitory neurons underlie striatal output imbalances in the dopamine depleted striatum ([@B75]). Striatal interneurons may also regulate basal ganglia plasticity ([@B21]) by modulating striatal extrinsic and intrinsic signals and thus may serve as a potential non-dopamine locus to lower striatal activity characteristic of PD.

Neurons derived from transplants of MGE tissue in striatum of the 6-OHDA lesioned mice migrate, functionally integrate and improve motor deficits ([@B78]). Under dopamine depleted conditions, striatopallidal neuronal activity is increased while the opposite is true for striatonigral neurons ([@B101]). Moreover, selective increase in feed-forward inhibition from local PV interneurons onto striatopallidal neurons enhances neural synchrony ([@B43]) which may lead to aberrant β-oscillatory activity characteristic of PD. Overall, GABA tone is increased in the basal ganglia ([@B10]) leading to persistent suppression of action. Since the transplanted cells show synaptic integration, one possible mechanism of action underlying therapeutic efficacy of MGE cells is the restoration of the balance between the direct and indirect pathways. However, it is notable that a large proportion of donor cells differentiate into oligodendrocytes, implicating non-neuronal support functions provided by the grafts (**Figure [2](#F2){ref-type="fig"}**). Intriguingly, MGE transplants made in the subthalamus fail to migrate from the injection site and instead differentiate into glial cells that show long term survival, highlighting the critical role donor-host environmental interactions may play in governing fate of transplanted progenitor cells.

Neuropathic Pain
================

In contrast to cortex, inhibitory interneurons form about 30--40% of the total neuronal population in the dorsal horn of the spinal cord. By regulating activity of primary afferents, excitatory interneurons, spinal projection neurons and descending fiber tracts, inhibitory interneurons play a crucial role in maintaining a physiological level of pain sensitivity. Disinhibition within the spinal dorsal horn has long been attributed to the symptoms of NP, e.g., GABA neurotransmission is significantly reduced following nerve injury ([@B83]; [@B34]) and GABA agonists can ameliorate allodynia and hyperalgesia ([@B85]). Impaired inhibition, however, results in multiple cellular, molecular and synaptic changes and therapeutic efficacy of currently available anticonvulsant- and antidepressant-based pharmacological agents is at best symptomatic and constrained by the drugs' broad mechanisms of actions. Given the ability of interneuron progenitors to functionally integrate in neural tissue and modify inhibitory signaling, interneuron transplantation could serve as a potential disease modifying strategy in NP that is without the adverse side effects associated with systemic medications.

Surprisingly, transplanted MGE cells into adult spinal cord differentiate into GABA interneuron populations that integrate with the host spinal cord circuitry ([@B11]). Contrary to subthalamic MGE grafts that differentiate into glial cells ([@B78]), MGE derived cells in the spinal cord retain their cortical neurochemical profiles suggesting that the latter does not affect MGE differentiation. More importantly, MGE transplantation reversed mechanical hypersensitivity in a mouse model of peripheral nerve injury ([@B11]) and mechanical and heat hyperalgesia in a chemotherapy-induced model of NP ([@B12]). Notably, transplantation of cells lacking vesicular GABA transporter failed to rescue paclitaxel-induced pain behavior highlighting the critical role of GABA-mediated modulation of spinal circuits in transplant efficacy in this pain model ([@B12]). Given the problems with tolerance and the sedative and addictive properties of traditional pharmacotherapies, interneuron based therapy may be a promising alternative disease modifying therapeutic option.

Challenges and Pitfalls in Using MGE Progenitor Cell Based Therapy
==================================================================

While pre-clinical studies have demonstrated promise for interneuron based therapy, cell based approaches have inherent limitations, including but not limited to unpredictable proliferation, differentiation, and migration, leading to pathological ectopia, including tumors. Addressing these limitations will require greater understanding of the mechanisms governing the development and function of the transplants in different brain regions and at different points in the lifespan of the host (**Figure [2](#F2){ref-type="fig"}**). Combined with these challenges, incomplete knowledge of the pathophysiology of vast majority of CNS diseases hinders progress to clinical translation. While excitement surrounds generation of GABAergic interneurons from human pluripotent stem cells ([@B77]; [@B118]), current techniques have yet to achieve sufficient efficiency and specificity. Technological innovations are leading to introduction of genetic material into transplanted cells to increase specificity, improvement in production methods allowing more rapid amplification, differentiation of stem cells, and use of cell sorting techniques to select cells on the basis of what will comprise a safe transplant designed specifically to improve function in a given brain region. Identifying host characteristics that can aid survival and guide maturation of the grafted cells *in vivo* will also address these challenges.

Conclusion
==========

The remarkable capacities of interneuron progenitors to migrate long distances, differentiate into mature interneurons and modify diseased circuits following transplantation have made interneuron based transplantation a viable potential therapeutic approach for CNS diseases. However, further studies in the primate, a refined knowledge of interneuron ontogenesis and development of methods for reliable, high-throughput production of specific GABAergic cell types and safe cell composition of transplants need to be pursued before this approach is realized in the clinical setting. There is reason to be optimistic, given rich and growing literature on interneuron development and rapid growth of technologies that will allow the production of safe and specific transplants.
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